Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 6/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416746 | 0.87 | PRKCI (0.40) | CHUKIKBKBROCK1PRKCICCNK | |
| SCHEMBL13505099 | 0.85 | PRKCI (0.39) | CHUKIKBKBROCK1PRKCICCNK | |
| SCHEMBL3417614 | 0.83 | PRKCI (0.37) | CHUKIKBKBROCK1PRKCICCNK | |
| SCHEMBL14279265 | 0.82 | CHUK (0.51) | CHUKIKBKBROCK1SIRT1PRKCI | |
| SCHEMBL3418231 | 0.82 | PRKCI (0.40) | CHUKIKBKBROCK1PRKCICCNK | |
| Trifluoroacetic Acid SCHEMBL3418240 | 0.80 | IKBKB (0.35) | CHUKIKBKBROCK1PRKCICCNK | |
| SCHEMBL3415216 | 0.79 | SMN1; SMN2 (0.45) | CDK12KDM4EALDH1A1 | |
| SCHEMBL13013845 | 0.79 | CCNK (0.39) | CHUKIKBKBROCK1PRKCICCNK | |
| SCHEMBL13507021 | 0.78 | IKBKB (0.34) | CHUKIKBKBROCK1PRKCICCNK | |
| SCHEMBL3418244 | 0.77 | IKBKB (0.34) | CHUKIKBKBROCK1PRKCICCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | disclosed |
| EP-2069341-B1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LTD (GB) | 2010-12-29 | — | — | EP | disclosed |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008034860-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | CHUK 8/4885IKBKB 4/4885ROCK1 467/4885 |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | PLK2, PDXK, MAP4K2 | CHUK 300/4885IKBKB 428/4885ROCK1 550/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | CHUK 8/4885IKBKB 4/4885ROCK1 467/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | CHUK 163/4885IKBKB 246/4885ROCK1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.